Gilead Sciences Inc. (GILD)
Gilead Sciences, Inc. (GILD) Annual Evercore ISI HealthCONx Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Annual Evercore ISI HealthCONx Healthcare Conference December 4, 2024 11:40 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore Umer Raffat Excellent. Well, thank you guys for joining us.
Gilead Sciences, Inc. (GILD) Piper Sandler 36th Annual Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Piper Sandler 36th Annual Healthcare Conference December 3, 2024 11:00 AM ET Company Participants Andy Dickinson - Chief Financial Officer Conference Call Participants Joe Catanzaro - Piper Sandler Joe Catanzaro Great. So thanks everybody for joining us here day one Annual Piper Sandler Healthcare Conference.
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?
GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
GILD vs. VRTX: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Gilead Sciences (GILD) and Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors?
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) 2024 Jefferies London Healthcare Conference November 20, 2024 4:30 AM ET Company Participants Dan O'Day - Chairman and CEO Andy Dickinson - CFO Conference Call Participants Michael Yee - Jefferies Michael Yee I'm Michael Yee, senior biotechnology analyst at Jefferies. And very pleased to have up on the front of this stage here with us the management team from Gilead.
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
On Friday, Gilead Sciences, Inc. GILD revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term efficacy and safety of Livdelzi.
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Gilead Sciences to close Seattle office; shutdown impacts 72 employees
Biopharma giant Gilead Sciences will shut down its office in Seattle's Eastlake neighborhood, the company confirmed to GeekWire on Wednesday.
Gilead initiated with a Buy at Citi
Citi initiated coverage of Gilead with a Buy rating and $125 price target. The firm says that despite the stock's near-term outperformance, it remains bullish based primarily on upside from Biktarvy led near-term HIV growth and lenacapavir driven long-term growth. It sees "upside growth" in Gilead's combined HIV franchise and believes lenacapavir "could boost" its next phase of growth.
